



Present Illness

- DM(+) for 20 yrs under OHA control, HTN(-), CVD(-), smoking(+), drinking(+)
- 1 month ago, cold sweating and tarry stool, poor appetite noted
- OGI upset, fatigue noted then he was sent to 忠孝 H.

Present Illness

- O Anemia noted, blood transfusion was done in 忠孝 H.
- Tarry stool with body weight loss 2 kg with in 2 weeks (58 kgs to 56 kgs)
- Adbomen echo
 - -- fatty liver, thicken wall of stomach

Present Illness

- **OPES**
 - -- one giant ulcerative tumor over supraangularis to high body, LCS to posterior wall
 - -- r/o gastric ca with bleeding
 - -- Biopsy: Large B cell Lymphoma (CD3-)(L26+)
- Ask our hospital for second opinion for further treatment



Personal history

- Smoking: social
- Alcohol:social
- Food allergy:nil
- ODrug allergy:nil
- Betel nut eating:nil
- Social activity:life style:active(+), sedentary()
- Oliving arrangement:normal(+), abnormal()

Medical history

• DM for 20+ years under OHA treatment.

Metformin

Amaryl

Avandia

Diovan

- Gastric B cell lymphoma: s/p CHOP; Mabthera
- UGI bleeding
- Surgical history : nil

Physical examination

- General appearance: chronic(+) ill-looking
- conjunctiva: pale(-), sclera: icteric(-)
- T/P/R__37.2__oC/__72__bpm/__20___pe r minute, BP__140_/_80__mmHg
- Chest: normal pattern
- Abdomen: no specific finding

• WBC [4.0-11.0 x10.e3/uL]

- HGB [12-18 g/dL]
- PLT [130-400 x10.e3/uL]
- %NEUT [40-74 %]
- ○%LYM [19-48 %]
- %MONO [2.0-10.0 %]
- %EOS [0-7 %]
- **9** %BASO [0-1.5 %]

Lab data

0.23

10.4

50

17.4

60.9

13.0

8.7

0.0

Lab data

●BUN (血液) [7-18 mg/dl]

• Creatinine(<u>m</u>)[0.5-1.3 mg/dl]

●GOT(血液) [0-40 IU/L]

●CRP (血液)[0.0-0.8 mg/dl]

●Na (血液)[135-158 meq/L]

●K (血液)[3.5-5.3 meq/L]

OStool OB: ++++

21

1.1

13

2.50

133.0

3.90



Lab data

HBsAg results(0.0-2.0 S/N)	0.84	
HBsAg (血液)	Negative	
Anti-HCV results[0-1.0 S/CO]	0.30	
Anti-HCV (血液)	Negative	
*B2-microglobulin(血液)(委外)[<2700ug/L]		2505.3

CXR:

- •Port-A catheter in place(4/15).
- •Linear densities over right upper lung field, may due to previous inflammatory process.
- •Normal heart size.
- •Normal appearance of bil. costo-phrenic angles.





- Stomach, large B cell lymphoma s/p CHOP and Mebthera therapy
- UGI bleeding
- DM with medical control of Metformin , Amaryl , Avandia , Diovan

04-1 PES:

esophagus: negative

stomach: much coffee ground material and blood clot. One giant ulcerative tumor over supra-angularis to high body, LCS to posterior wall. Mild oozing.

-- r/o gastric ca with bleeding duodenum: negative to 2nd portion

- 4-2 abdomen echo: mild fatty liver
 thicken wall of the stomach
- 4-8 biopsy: CD3(-); L26(+)

Stomach, supra-angularis to the body, lesser curvature site, posterior wall, endoscopic biopsy, showing B cell lymphoma

- 4-12 Gallium scan:
 diffuse inflammation or neoplastic process of the stomach
- 4-13 Abd MRI s/c Gd-DTPA gastric B-cell lymphoma

- 4-14 Hb 6.0; MCV 93.0; PLT 227; BUN 22
- 4-16 LDH 284
- 4-19 Cardiac echo:


EF: 76 %


normal LV function, trivial TR and MR

• 4-23 BM biopsy:

normocellular marrow with myeloid hyperplasia. No tumor involved

- 4-28 Hb 10.4; WBC 230; Neu 17.4
- Medication:
- 1.CHOP and Mabthera were for B-cell lymphoma
- 2. Alkalization of urine was for tumor lysis syndrome.
- 3.GCSF was for leukopenia






Radiology thinking process

thickened gastric folds

Hyperacidic disease	Peptic ulcer disease	
	Zollinger-Ellison disease	
hypoproteinemia		
lymphoma		
pseudolymphoma		
Eosinophilic gastroenteri	itis	
varices		
Menetrier disease		
IBD, TB, syphilis		






Menetrier disease


Advanced gastric cancer, carcinoma

Gastric lymphoma

Gastric inflammation

- H. pylori infection leads to gastric inflammation
- surface epithelial degeneration and infiltration of the gastric mucosa
- H. pylori chemotaxins, chemokines such as IL-8 and GRO-alpha, and pro-inflammatory cytokines liberated by mononuclear phagocytes (TNF alpha, IL-1 and IL-6) as part of non- specific immunity.





Menetrier's disease


- hypertrophic gastritis
- thickened gastric rugae with sparing of antrum
- epithelial-cell hypertrophy
- protein wasting
- mucus production increased
- acidity: normal or decreased


Menetrier's disease

- causes giant folds of tissue to grow in the wall of the stomach.
- The tissue may contain ulcers.
- Menetrier's disease increases a person's risk of stomach cancer.
- The cause of the disease is unknown.

Menetrier's disease

- also called giant hypertrophic gastritis, protein losing gasteropathy, or hypertrophic gastropathy.
- Symptoms include discomfort and tenderness in the top middle part of the abdomen, loss of appetite, nausea, diarrhea, vomiting blood, and ulcer-like pain after eating





Gastric malignancies

- 3rd most common GI malignancy (after colorectal + rectal).
- The stomach is the site of variety of malignant neoplasms. They are primary carcinoma, gastric lymphoma, mesenchymal tumours and metastatic carcinomas.
- The most common of these are carcinoma and lymphoma.

Gastric malignancies

- predisposing factors:
- pernicious anemia (2X risk)
- chronic atrophic gastritis
- adenomatous + villous polyp
- gastrojejunostomy

Gastric malignancies

- (1) Gastric adenocarcinoma: 85%
- (2) Gastric lymphoma: 5%
- (3) Metastatic Disease:
 - 1.malignant melanoma
 - 2.breast carcinoma
 - 3. esophagus, pancreas, transverse colon
- (4)Leiomyosarcoma: large exophytic cavitated mass
- (5)Kaposi' sarcoma

Gastric carcinoma morphology

Primary carcinoma of the stomach may be present as:

1. Superficial spreading carcinoma (Early gastric cancer)

Type I lesions are elevated and protrude more than 5 mm into the lumen.

Type II tumors are superficial lesions that are elevated (IIa), flat (IIb), or depressed (IIc).

Type III early gastric cancers are shallow, irregular ulcers surrounded by nodular, clubbed mucosal folds.

Gastric carcinoma morphology

- 2. Polypoid or fungating carcinoma
- 3. Ulcerating or penetrating carcinoma(70%)
- 4. Advanced bulky carcinoma
- 5. Infiltrating or cirrhous carcinoma(5~15%) (linitis plastica)

Gastric carcinoma location

- ●60% lesser curvature
- 30% GE junction
- 10% greater curvature
- probability of malignancy of an ulcer
 - --fundus 90%
 - -- greater curvature 70%
 - --lesser curvature 10-15%

Gastric carcinoma UGI

- A.benign,projecting,l esser curvature ulcer with collar.
- B.malignant,intralum inal ulcer with irregular nodular tumor rim.
- C.nonprojecting benign great curvature ulcer




Gastric carcinoma UGI


Scirrhous carcinoma of the stomach(linitis plastica)






Fig. 8. A. Scirrhous carcinoma of the stomach (linitis plastica). The proximal two thirds of the stomach is involved with scirrhous carcinoma. The stomach is narrowed, shrunken, and rigid. The normal mucosal fold pattern has been replaced by thickened, irregular rugae infiltrated with cancer. A discrete ulcerating lesion is not identified. During fluoroscopy, peristalsis was absent, and barium flowed through the stomach by gravity as through a rigid tube. B. Air-contrast study reveals the distal half of the stomach to be irregularly narrowed and tubular. The mucosa is thickly infiltrated with scirrhous carcinoma.







Gastric lymphoma

- Radiographic type:
 - 1. Polypoid or nodular (47%) enlarged nodular folds
 - 2. Ulcerative (42%)
 ulcerative lesions, may be complicated by perforation; aneurysmal configuration
 - 3. Diffusely infiltrating(11%)

diffuse hoselike thickening of bowel; decreased or absent peristalsis

Gastric lymphoma UGI

- 1. Infiltrative, ulcerative, or nodular mass that often mimics the appearance of adenocarcinoma. Flexibility of gastric wall preserved.
- 2. The antrum and body are most commonly involved. Duodenum often affected when antrum involved.
- 3. Circumscribed mass with endogastric or exogastric growth
- 4. Large irregular ulcers

Gastric lymphoma CT

- 1. diffuse involvement of entire stomach, typically more than half of gastric circumference
- 2. segmental involvement
- 3. thickened gastric wall
- 4. luminal irregularity, hyperrugosity
- spread of the tumor: direct extension into pancreas, spleen, transverse colon and liver



Lymphoma grade

O Low grade:

ML, small lymphocytic

ML, follicular small cleaved cell

ML, follicular, mixed small and large cell

• Intermediate grade:

ML, follicular, large cell

ML, diffuse, small cleaved cell

ML, diffuse, mixed small and large cell

ML, diffuse large cell

• High grade:

ML, large cell, lymphoblastic

ML, lymphoblastic

ML, small non-cleaved cell

Lymphoma

	Hodgkin	non-Hodgkin	
Presentation	Usually nodal	Usually extranodal	
Spread	Contiguous	Hematogenous, Non- contiguous	
Mediastinum	Common	Uncommon(except lymphoblastic type)	
Spleen	Common	Uncommon	
Bone Marrow	Uncommon	Common	
Liver, GI, CNS	Uncommon	Common	

Hodgkin's Lymphoma

Hodgkin's lymphoma
 Young adult
 Malignant Reed-Sternberg cell
 CD30(+), CD20(+/-)

	CD30	CD20
Lymphocyte-predominant	+	+
Classic Hogkin's	+	-

Hodgkin's Lymphoma

- OL-P (nodular growth pattern), popcorn cell
- Classic Hogkin's
 - 1. Lymphocyte rich (LR): rare RS
 - 2. Mixed cellularity (MC): EBV-associated
 - 3. Lymphocyte depletion (LD): RS
 - 4. Nodular sclerosis (NS): Lacuna RS + fibrous background, women, mediastinum

Non-Hodgkin's Lymphoma

Small lymphocytic lymphoma

CD5(+), older adult, Richter's transformation, paraneoplastic syndrome

Waldenstrom's macroglobulinemia

IgM, hyperviscosity

• Mantle cell lymphoma

t(11,14), BCL1, GI lymphomatoid polyposis

• MALT lymphoma

t(11,18), lymphoepithelial lesion

Non-Hodgkin's Lymphoma

• Follicular lymphoma

t(14,18), bcl2, Nodular growth pattern

Diffuse large B-cell lymphoma

Diffuse growth pattern, autoimmune disorder, EBV, plasma cell, aggressive behavier

Burkitt's lymphoma

t(8,14), oncogene myc, EBV, starry-sky pattern

Non-Hodgkin's Lymphoma

- Anaplatic large cell lymphoma (ALCL) young adult , good prognosis
- T-lymphoblastic lymphoma anterior mediastinum
- Mycosis fungoides / Sezary syndrome skin T-cell lymphoma, cerebriform, Pautrier microabscess
- Adult T-cell leukemia-lymphoma
 HTLV-1 retrovirus, hypercalcemia

Gastric lymphoma

- Primary gastric lymphomas: less than 2% of all primary stomach malignancies
- Non Hodgkin's type and of B-cell lineage
- almost 75% of primary gastrointestinal lymphomas were of gastric origin.
- Gastric lymphomas are more prevalent in patients over the age of 50, and men are affected two to three times more frequently than women

Gastric lymphoma

- Usually arise from MALT (mucosa associated lymphoid tissue)- also known as Marginal Zone B-cell lymphoma (Low and High grade).
- O Diffuse large B-cell lymphoma include high grade lymphoma of MALT origin and non-MALT type and they are indistinguishable

Gastric lymphoma: clinic sign

- Most common: pain , weight loss, nausea and vomiting, anorexia, and bleeding.
- Early symptoms are vague .
- More advanced lesions may present with hemorrhage, pyloric stenosis, or signs of perforation.
- PE:Abdominal tenderness, a palpable abdominal mass, hepatomegaly
- No physical finding : 62 %

Gastric lymphoma: Stage

• Musshoff's criteria staging system

Stage IE: limited to the GI stomach

Stage IIE1: regional lymph node

Stage IIE2: noncontigious subdiaphragmatic

lymph node

Stage III: spread to other organs within the abdomen

Stage IV: hematogenous spread

Gastric Lymphoma: Prognosis

IPSS (International prognostic scoring system)

```
Diffuse large B cell lymphoma
1. Age>60y/o
2. Musshoff's criteria stage III or IV
3. Extranodal involvement >1 site
```

- 4. Poor performance status (ECOG 2~4) 5. High LDH

Risk: low(<1), low-intermediate(2),
intermediate-high(3), high(4~5)

Surgery:

- No decrease in survival for patients if adjuvant RT or C/T were given than total resection of all gross disease and involved lymph nodes.
- 2. In surgically treated patients, most recurrences are extraabdominal and local disease is well controlled.
- 3. Currently, splenectomy is only indicated in cases of direct tumor extension.

• Radiotherapy:

Gastric lymphoma seems to be a more systemic disease

In the absence of obvious persistent local disease, the need for additional local therapy with RT is put in question.

Chemotherapy:

- 1. As stated earlier, the diffuse large cell type is the most. They are quite responsive to current chemotherapy.
 - 2. Stages IE & IIE treated with chemotherapy after surgery: excellent 5-year disease free survival

• C/T regimens:

CHOP (cyclophosphamide, Adriamycin,
vincristine, prednisone)
CHOP-bleo (+ bleomycin)
COPP-bleo (cyclophosphamide, vincristine,
procarbazine, prednisone, bleomycin) CVP
(cyclophosphamide, vincristine, and
prednisone)



OC/T

Aggressive course without tratment 80% complete remission rate by C/T 40% cure by C/T

Gastric Lymphoma: conclusion

Early stage:

Surgery: for local control and preoperative staging

Adjuvant C/T: for extraabdominal lesion

Invasion stage:

C/T: treatment with either surgery or radiation providing local control.

In those patients with non-diagnostic biopsies, surgical exploration and resection are needed.